Abstracts tagged "risk factors"

Abstract Number: 2378 • ACR Convergence 2025
Factors Associated With Fatigue In Systemic Lupus Erythematosus: Data From The Almenara Lupus Cohort
Alvaro Oyarce-Calderón¹, Rocío Gamboa-Cárdenas², Victor Pimentel-Quiroz³, Samira Garcia-Hirsh⁴, Zoila Rodríguez-Bellido⁵, Cesar Pastor-Asurza⁶, Risto Perich-Campos⁷, Graciela Alarcón⁸ and Manuel Ugarte-Gil⁹, ¹Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Lima, Peru, ²Universidad Científica del Sur, Lima, Peru, ³Universidad Científica del Sur, San Isidro, Peru, ⁴Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen, Lima, Pakistan, ⁷Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁸The University of Alabama at Birmingham, Oakland, CA, ⁹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by a wide spectrum of clinical manifestations, fatigue being one of them; it is…
Abstract Number: 1700 • ACR Convergence 2025
Altered Gene Expression In Male SLE Is Mapped To a Male-Specific Y Chromosome Locus Associated with Microdeletions
Mikhail Olferiev¹, Kyriakos Kirou¹, Emily Wu², Dina Greenman¹ and Mary Crow³, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Union City, NJ, ³Hospital for Special Surgery, New York
Background/Purpose: SLE occurs more frequently in females than males, with relative prevalence 9-10:1. While the impact of hormones on immune function may contribute to the…
Abstract Number: 1137 • ACR Convergence 2025
Increased Risk of Cardiovascular Events and Mortality Related to Diffuse Idiopathic Skeletal Hyperostosis (DISH): A Systematic Review and Meta-Analysis
Pitchaporn Yingchoncharoen¹, Nattanicha Chaisrimaneepan², Miriam Paz³, Chanokporn Puchongmart¹, Ben thiravetyan¹, Panat Yanpiset¹ and Jerapas Thongpiya⁴, ¹Texas Tech Health Sciences Center, Lubbock, TX, ²Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, ³Texas Tech University Health Sciences Center, Lubbock, ⁴Texas Tech University Health Sciences Center at Lubbock Program, Lubbock, TX
Background/Purpose: Diffuse Idiopathic Skeletal Hyperostosis (DISH) is characterized by ossification and calcification of the entheses with prevalence increasing with age. It has been reported to…
Abstract Number: 0831 • ACR Convergence 2025
Altered expression of CD11c and HLA-DR on monocyte subsets in individuals at risk of rheumatoid and psoriatic arthritis
Klára Prajzlerová¹, Olga Kryštůfková², Hana Hulejová¹, Nora Růžičková², Petra Hánová¹, Jiri Vencovsky³, Ladislav Šenolt², Jiří Štolfa² and Mária Filková², ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ³Institute of Rheumatology, Praha ⁸, Czech Republic
Background/Purpose: Preclinical phases of rheumatoid arthritis (RA), including therapeutic interventions, have been extensively studied. There is a growing focus on individuals at risk for psoriatic…
Abstract Number: 0142 • ACR Convergence 2025
Risk Factors for Antiphospholipid Syndrome-associated Nephropathy: A Retrospective Cohort Analysis
Xiaohan Wei¹, Zhixia Yang², Haoyu Pan², Yuying Fan², Jinyi Qian², Shuyi Yu² and Hui Shi³, ¹Shanghai JiaoTong University, Shanghai, China (People's Republic), ²Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ³Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)
Background/Purpose: To identify independent clinical and laboratory risk factors associated with antiphospholipid syndrome-associated nephropathy (APSN) and highlight the clinical importance of early screening in high-risk…
Abstract Number: 2323 • ACR Convergence 2025
Short-term predictive factors for the development of psoriatic arthritis in patients with psoriasis: findings from a joint consultation between Rheumatology and Dermatology
Mitndbaim Parra¹, Marta Flores², María Ángeles Puche-Larrubia³, Alejandro Escudero Contreras⁴, María Dolores López-Montilla⁵ and Clementina López Medina⁶, ¹¹. Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., Cordoba, Spain, ²¹. Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., Spain, Spain, ³Reina Sofia University Hospital, Granada, Spain, ⁴IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁵Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., CORDOBA, Spain, ⁶Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain
Background/Purpose: Psoriatic Arthritis (PsA) is a chronic rheumatic disease that develops in up to one-third of patients with psoriasis. Identifying predictive factors for PsA in…
Abstract Number: 1681 • ACR Convergence 2025
Lymphoma and Other Malignancies in Sjögren’s Disease: Incidence, Predictive Factors, and Mortality Outcomes.
Olga Rusinovich¹, Zulema Plaza², Monica Fernandez Castro³, Jose Rosas Gómez de Salazar⁴, Victor Martinez-Taboada⁵, Alex Olive⁶, Belén Serrano-Benavente⁷, Judit Font-Urgelles⁸, Angel Garcia-Aparicio⁹, Sara Manrique-Arija¹⁰, Jesús Alberto Garcia Vadillo¹¹, Ruth Lopez-Gonzalez¹², Javier Narváez¹³, Maria Beatriz Rodriguez¹⁴, Carlos Galisteo¹⁵, Jorge Juan Gonzalez Martin¹⁶, Paloma Vela Casasempere¹⁷, Rabadán Elena¹⁸, Antonio Naranjo¹⁹, Beatriz Paredes-Romero²⁰, Leyre Riancho-Zarrabeitia²¹, Sheila Melchor Diaz²², Irene Altabás-González²³, Sergi Heredia Martin²⁴, Clara Moriano²⁵, Mª Angeles Blazquez Cañamero²⁶, Paula Estrada-Alarcón²⁷, Enrique Judez²⁸, Nerea Alcorta Lorenzo²⁹, Javier Loricera³⁰, Rosalía Martínez Pérez³¹, Fernando Sánchez-Alonso³² and Jose Luis Andreu³³, ¹Puerta de Hierro University Hospital, Boadilla del Monte, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, Madrid, Spain, ³PUERTA DE HIERRO HOSPITAL, Madrid, Spain, ⁴Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ⁵Facultad de Medicina. Universidad de Cantabria, Santander, Spain, ⁶Solo practice, Barcelona, Spain, ⁷Hospital Gregorio Marañon, Madrid, Spain, ⁸Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁹Hospital Universitario de Toledo, Toledo, Spain, ¹⁰Hospital Regional Universitario Málaga, Malaga, Spain, ¹¹Hospital Universitario La Princesa, Madrid, Spain, ¹²Zamora Health Complex, Salamanca, Spain, ¹³Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁴Canarias University Hospital, La Laguna- Tenerife, Spain, ¹⁵Hospital Parc Taulí, Sabadel, Sabadel, Spain, ¹⁶HM Sanchinarro Univeristary Hospital, Madrid, Spain, ¹⁷Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁸Hospital Universitario Príncipe de Asturias, Alcala de Henares, Spain, ¹⁹Hospital Dr Negrin, PALMAS DE GRAN CANARIA (LAS), Spain, ²⁰Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de los Reyes, Spain, ²¹Rheumatology Department. Hospital Sierrallana, Torrelavega, Spain, ²²¹² de Octubre University Hospital, Madrid, Spain, ²³Complejo Hospitalario de Vigo, Vigo, Spain, ²⁴Complex Hospitalari Moisès Broggi, Barcelona, Spain, ²⁵Hospital León, LEON, Castilla y Leon, Spain, ²⁶Hospital Ramon y Cajal, Madrid, Spain, ²⁷Complex Universitari Hospital Moisès Broggi, Barcelona, Spain, ²⁸Albacete University Hospital, Albacete, Spain, ²⁹University Hospital Donostia, san sebastian, Spain, ³⁰Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³¹Hospital Universitario Virgen de Valme, Servicio de Reumatología, Seville, Spain, ³²Sociedad Española de Reumatología, Madrid, Spain, ³³Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: The association between Sjögren’s disease (SjD) and non-Hodgkin lymphoma (NHL) is well established, although reported standardized incidence ratios (SIRs) vary considerably across studies. In…
Abstract Number: 1109 • ACR Convergence 2025
Characteristics of SARS-CoV-2 infected Patients with Rheumatic Diseases on Rituximab: A Subanalysis of the COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD) Study
Laurianne Simard¹, Nathalie Amiable², Ines Colmegna³, Anne-Sophie Julien⁴, Sonia Léger-Thériault⁵, Alexandra Godbout⁴, Lison Fournier⁶, Giuliana Alfonso⁵, Josiane Bourre-Tessier⁷, Marie Hudson⁸, Nicolas Richard⁹, Jean-Paul Makhzoum¹⁰, Arielle Mendel¹¹, Sasha Bernatsky¹², Marc Dionne⁶, Michael Libman⁵, Gaston De Serres⁶ and Paul Fortin¹³, ¹Universite Laval, Quebec, QC, Canada, ²Centre de recherche du CHU de Québec – Université Laval, Quebec City, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴Centre de recherche du CHU de Québec – Université Laval, Quebec, QC, Canada, ⁵MUHC, Montreal, Canada, ⁶Centre de recherche du CHU de Québec – Université Laval, Quebec, Canada, ⁷Centre hospitalier de l'Universite de Montreal, Montreal, QC, Canada, ⁸McGill University, Montréal, QC, Canada, ⁹Hopital Maisonneuve Rosemont, Montreal, QC, Canada, ¹⁰Universite de Montreal, Montreal, Canada, ¹¹McGill University Health Centre, Montréal, QC, Canada, ¹²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹³Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada
Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARD) treated with B-cell-depleting therapies such as rituximab (RTX) have impaired humoral immune responses, increasing their susceptibility to…
Abstract Number: 0786 • ACR Convergence 2025
A Machine Learning Approach to Understand Age as a Risk Factor for Complications After Total Hip Arthroplasty
Chloe Heiting¹, Yiyuan Wu², Susan Goodman³, Peter Sculco⁴, Fei Wang², Rich Caruana⁵, Peter Cram⁶, Said Ibrahim⁷ and Bella Mehta⁸, ¹Northwell Health, New Hyde Park, NY, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Hospital for Special Surgery, New York, NY, ⁵Microsoft, Redmond, WA, ⁶University of Maryland School of Medicine, Baltimore, MD, ⁷Thomas Jefferson University, Philadelphia, PA, ⁸Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ
Background/Purpose: Utilization of total hip arthroplasty (THA) has grown rapidly in the United States and worldwide. Postoperative complications and patient risk is of great consideration…
Abstract Number: 0133 • ACR Convergence 2025
Differences in cardiovascular risk factor control between primary and systemic lupus erythematosus-related antiphospholipid syndrome in a multiethnic cohort of 1003 patients with antiphospholipid syndrome: the SUrvey of cardiovascular disease Risk Factors (SURF) in SLE and APS project
Eleana Bolla¹, Anne Grete Semb², Michelle Petri³, Petros Sfikakis⁴, Bahar Artim Esen⁵, Gabriela Hernandez-Molina⁶, Eric Hachulla⁷, Haner Direskeneli⁸, George Karpouzas⁹, Marta Mosca¹⁰, Mohit Goyal¹¹, Nathalie Costedoat-Chalumeau¹², Angela Tincani¹³, Ayten Yazici¹⁴, Karoline Lerang¹⁵, Anne Troldborg¹⁶, Sofia Ajeganova¹⁷, Tatiana Popkova¹⁸, Elisabet Svenungsson¹⁹, Nikos Pantazis²⁰ and Maria Tektonidou²¹, ¹Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece, ²Preventive Cardio-Rheuma clinic, Dept Rheum, Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴NKUA - SCHOOL OF MEDICINE, Athens, Greece, ⁵Istanbul University, Istanbul, Istanbul, Turkey, ⁶Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Federal District, Mexico, ⁷University of Lille, LILLE, France, ⁸Marmara University, ISTANBUL, Turkey, ⁹Harbor-UCLA Medical Center, Torrance, CA, ¹⁰University of Pisa, Pisa, Pisa, Italy, ¹¹CARE Pain & Arthritis Centre, Udaipur, Rajasthan, India, ¹²Inserm DR Paris ⁵, Paris, France, ¹³ASST Spedali Civili-University of Brescia, Gussago, Brescia, Italy, ¹⁴Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey, ¹⁵Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ¹⁶Aarhus University Hospital, Aarhus, Denmark, ¹⁷Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden, ¹⁸V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ¹⁹Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ²⁰Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece, ²¹National and Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Cardiovascular disease (CVD) in antiphospholipid syndrome (APS) is driven by antiphospholipid antibody-mediated immunothrombotic mechanisms and traditional cardiovascular risk factors (CVRFs). Although the EULAR recommendations…
Abstract Number: 2286 • ACR Convergence 2025
Association of Semaglutide Prescription with Improved Joint Outcomes in Rheumatoid Arthritis Patients
Faissal Stipho¹, Yazin Hindosh², Jonathan Sayegh², Akram Hindosh², Bassam Mitri² and Issa Batarseh¹, ¹Department of Internal Medicine, Banner University Medical Center / University of Arizona, Tucson, Arizona, Tucson, AZ, ²University of Arizona College of Medicine Tucson, Tucson, AZ
Background/Purpose: Rheumatoid Arthritis (RA) is an autoimmune disorder that results in immune dysfunction and swelling of major joints, leading to discomfort, pain, stiffness, and loss…
Abstract Number: 1635 • ACR Convergence 2025
Association Between Treatment Adherence and Frailty in Patients with Rheumatic Diseases
Daniela L. Guillen-Tejada¹, Aura Matilde Jiménez-Garduño¹ and Montserrat Lamuño Encorrada², ¹Universidad de las Américas Puebla, Puebla, Mexico, ²Hospital Ángeles Puebla, Puebla, Mexico
Background/Purpose: Management of rheumatic diseases relies on chronic treatment, often with a greater risk of nonadherence. Frailty is characterized by decreased physiological function that increases patients’…
Abstract Number: 1104 • ACR Convergence 2025
Immune Checkpoint Inhibitors and Cardiovascular Risk in Patients with Rheumatoid Arthritis and Cancer
Kevin Sheng-Kai Ma¹, Rachael Stovall², Jeffrey Sparks³, You Wu², Richard Cheng⁴, Gregory Challener⁵, Hans von Eckstaedt², Bhavik Bansal⁶, Petros Grivas⁷, Steven Chen⁸, Jean Liew⁹ and Namrata Singh⁷, ¹Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Philadelphia, PA, ²University of Washington, Seattle, WA, ³Brigham and Women's Hospital, Boston, MA, ⁴University of Washington, Seaattle, WA, ⁵MGH, Boston, MA, ⁶UT Southwestern Medical Centre, Dallas, TX, ⁷University of Washington, BELLEVUE, WA, ⁸Massachusetts General Hospital, Boston, ⁹Boston University, Boston, MA
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) face a higher lifetime burden of cardiovascular disease (CVD) vs the general population with approximately 1.5-2-fold increase in…
Abstract Number: 0778 • ACR Convergence 2025
Clinical significance of non-infectious increased procalcitonin in Still’s disease: A predictor of macrophage activation syndrome
Erdem Bektas¹, Burcu Ceren Uludogan², Büşra Fırlatan Yazgan³, Ozgur Can Kilinc⁴, Beste Acar⁴, Oguzhan Omer Kizilkaya⁴, Aysenur Yilmaz⁵, Busra Yuce⁶, serdal Ugurlu⁷, Umut Kalyoncu³, Timucin Kasifoglu² and Cemal Bes⁸, ¹Istanbul University, Institute of Graduate Studies in Health Sciences, Immunology, Istanbul, Turkey, ²Division of Rheumatology, Department of Internal Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey, ³Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, ⁴Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁵Department of Rheumatology, Basaksehir Cam and Sakura City Hospital, University of Health Sciences, Istanbul, Turkey, ⁶Department of Internal Medicine, Basaksehir Cam and Sakura City Hospital, University of Health Sciences, Istanbul, Turkey, ⁷Istanbul University-Cerrahpasa, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁸University of Health Sciences, Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey
Background/Purpose: Still's disease (SD) is a autoinflammatory disease (AID) characterized by a wide range of clinical manifestations and can exhibit life-threatening macrophage activation syndrome (MAS).…
Abstract Number: 0120 • ACR Convergence 2025
The Prevalence and Clinical Significance of Heritable Thrombophilia in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry
Emre Sahin¹, Maria Efthymiou², Danieli Andrade³, Megan Barber⁴, Maria Tektonidou⁵, Vittorio Pengo⁶, Massimo Radin⁷, Jose Pardos-Gea⁸, MARIA ANGELES AGUIRRE ZAMORANO⁹, Nina Kello¹⁰, Diana Paredes-Ruiz¹¹, H Michael Belmont¹², Paul Fortin¹³, Denis WAHL¹⁴, Ware Branch¹⁵, Maria Gerosa¹⁶, Guilherme Ramires de Jesus¹⁷, Zhuoli Zhang¹⁸, Tatsuya Atsumi¹⁹, Giulia Pazzola²⁰, Laura Andreoli²¹, Ali Duarte-Garcia²², Esther Rodriguez-Almaraz²³, Michelle Petri²⁴, Ricard Cervera²⁵, Bahar Artim Esen²⁶, Guillermo Pons-Estel²⁷, Hui Shi²⁸, Jason S. Knight²⁹, Rohan Willis³⁰, Maria Laura Bertolaccini³¹, Hannah Cohen³² and Doruk Erkan¹, ¹Hospital for Special Surgery, New York, NY, ²University College London, London, United Kingdom, ³University of Sao Paulo, São Paulo, São Paulo, Brazil, ⁴Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵National and Kapodistrian University of Athens, Athens, Greece, ⁶Padova University Hospital, Padova, Italy, ⁷University of Turin, Turin, Turin, Italy, ⁸Vall d’Hebron University Hospital, Barcelona, Spain, ⁹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ¹⁰Northwell Health, Brooklyn, NY, ¹¹Biobizkaia Health Research Institute, Barakaldo, Spain, ¹²NYU School of Medicine, New York, NY, ¹³Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹⁴University of Lorraine, Nancy, France, ¹⁵University of Utah Health Sciences Center, Salt Lake City, UT, ¹⁶University of Milan, Milano, Italy, ¹⁷Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Rio de Janeiro, Brazil, ¹⁸Peking University First Hospital, Beijing, Beijing, China (People's Republic), ¹⁹Hokkaido University, Sapporo, Japan, ²⁰Rheumatology Unit, Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy, ²¹University of Brescia, Brescia, Brescia, Italy, ²²Mayo Clinic, Rochester, MN, ²³Hospital Universitario ¹² de Octubre, Madrid, Spain, ²⁴Johns Hopkins University School of Medicine, Timonium, MD, ²⁵Hospital Clinic Barcelona, Barcelona, Spain, ²⁶Istanbul University, Istanbul, Istanbul, Turkey, ²⁷Centro Regional de Enfermedades Autoinmunes y Reumáticas, GO-CREAR, Rosario, Argentina, Rosario, Argentina, ²⁸Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic), ²⁹University of Michigan, Ann Arbor, MI, ³⁰University of Texas Medical Branch, Galveston, TX, ³¹King's College London, London, United Kingdom, ³²University College London Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: Although antiphospholipid antibodies (aPL) are well-established risk factors for thrombosis, heritable thrombophilias (HT) are also associated with venous thromboembolism (VTE). The latter includes deficiencies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].